A review of NMDA receptors and the phencyclidine model of schizophrenia

Pharmacotherapy

Volumn 16, Issue 1 I, 1996, Pages 82-93

  Thornberg, Sheri A ^a,c   Saklad, Stephen R ^b  

^a RUTGERS UNIVERSITY   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PHENCYCLIDINE;

4 AMINOBUTYRIC ACID RELEASE; DOPAMINE RELEASE; HUMAN; NEUROTRANSMISSION; PATHOPHYSIOLOGY; PSYCHOSIS; REVIEW; SCHIZOPHRENIA;

BRAIN CHEMISTRY; EXCITATORY AMINO ACID ANTAGONISTS; GAMMA-AMINOBUTYRIC ACID; HISTORY, 20TH CENTURY; PHENCYCLIDINE; PSYCHOSES, SUBSTANCE-INDUCED; RECEPTORS, N-METHYL-D-ASPARTATE; SCHIZOPHRENIA; SYNAPTIC TRANSMISSION;

EID: 0030041171     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (122)

1. Collins V, Gorospe C, Rovenstine E. Intravenous nonbarbiturate, nonnarcotic analgesics: preliminary studies. Anesth Analg 1960,39:303-6.
2. Greifenstein F, Yoskitake J, DeVault M, Gajewski J. A study of 1-aryl-cyclohexylamine for anesthesia Anesth Analg 1958,37:283-94.
3. Johnstone M, Evans V, Baigel S Sernyl (Cl-395) in clinical anaesthesia. Br J Anaesth 1958,31 433-9.
4. Sioris L, Krenzelok E. Phencydidine intoxication: a literature review. Am J Hosp Pharm 1978,35:1362-7
5. Davies BM, Beech HR. The effect of 1-arylcyclohexylamine (Sernyl) on twelve normal volunteers. J Ment Sci 1960;106.912-24
6. Cohen BD, Rosenbaum G, Luby ED, Gottlieb JS Comparison of phencyclidine hydrochloride (Sernyl) with other drugs simulation of schizophrenic performance with Sernyl, lysergic acid diethylamide (LSD-25), and amobarbital (Amytal) sodium II. Symbolic and sequential thinking. Arch Gen Psychiatry 1962,6 79-85.
7. Rosenbaum G, Cohen BD, Luby ED, Gottlieb JS, Yelen D. Comparison of phencyclidine hydrochloride (Sernyl) with other drugs: simulation of schizophrenic performance with Sernyl, LSD-25, and amobarbital (Amytal) sodium 1 Attention, motor function, and proprioception. Arch Gen Psychiatry 1959;1:651-6.
8. Meyer J, Greifenstein F, DeVault M. A new drug causing symptoms of sensory deprivation J Nerv Ment Dis 1959,129:54-61.
9. Bakker C, Amini F. Observations on the psychotomimetic effects of Sernyl Compr Psychiatry 1961,2.269-80.
10. Luby E, Cohen B, Rosenbaum F, Gottlieb J, Kelley R. Study of a new schizophrenomimetic drug, Sernyl Arch Neurol Psychiatry 1959,81:363-9
11. Itil T, Keskiner A, Kiremitci N, Holden J. Effect of phencyclidine in chronic schizophrenics. Can Psychiatr Assoc J 1967,12:209-12
12. Ban TA, Lohrenz JJ, Lehmann HE. Observations on the action of Sernyl - a new psychotropic agent Can Psychiatr Assoc J 1961;6:150-7.
13. Richards M, Perry P, Liskow B. Phencychdine psychosis. Drug Intell Clin Pharm 1979,13:336-9.
14. Fauman B, Aldinger G, Gauman M, Rosen P. Psychiatric sequelae of phencyclidine abuse Clin Toxicol 1976;9 529-38.
15. Luby E, Gottlieb J, Cohen B, Rosenbaum G, Domino E. Model psychoses and schizophrenia Am J Psychiatry 1962,119:61-7.
16. Krystal JH, Karper LP, Seibyl JP, et al Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994;51:199-214
17. Fagg G, Foster A, Ganong A. Excitatory amino acid synaptic mechanisms and neurological function Trends Pharmacol Sci 1986;7:357-63.
18. Fagg G, Foster A. Amino acid neurotransmitters and their pathways in the mammalian central nervous system. Neuroscience 1983;4:707-19.
19. Meldrum B. Possible therapeutic applications of antagonists of excitatory amino acid neurotransmitters Clin Sci 1985;68:113-22
20. Szerb JC. Rate limiting steps in the synthesis of GABA and glutamate In: Avoli M, Reader TA, Dykes RW, Gloor P, eds. Neurotransmitters and cortical function from molecules to mind New York: Plenum Press, 1988 153-66.
21. Cotman C, Monaghan D Chemistry and anatomy of excitatory ammo acid systems In: Meltzer HY, ed. Psychopharmacology. the third generation of progress. New York: Raven Press, 1987 197-210.
22. Watkins J, Evans R. Excitatory ammo acid transmitters. Annu Rev Pharmacol Toxicol 1981,21.165-204
23. Nakanishi S. Molecular diversity of glutamate receptors and implications for brain function Science 1992;258:597-603.
24. 2+ permeability of KA-AMPA-gated glutamate receptor channels depends on subunit composition. Science 1991;252:851-3.
25. Javitt D, Zukin S. The role of excitatory ammo acids in neuropsychiatrie illness. J Neuropsychiatry Clin Neurosci 1990;2:44-52.
26. Schoepp D, Bockaert J, Sladeczek F. Pharmacological and functional characteristics of metabotropic excitatory amino acid receptors. Trends Pharmacol Sci 1990;11:508-14.
27. Baraban JM, Worley PF, Snyder SH. Second messenger systems and psychoactive drug action: focus on the phosphoinositide system and lithium. Am J Psychiatry 1989;146 1251-60
28. Cotman C, Iversen L. Excitatory amino acids in the brain - focus on NMDA receptors. Trends Neurosci 1987;10:263-5.
29. MacDermott A, Mayer M, Westbrook G, Smith S. NMDA-receptor activation increases cytoplasmic calcium concentration in cultured spinal cord neurones Nature 1986,321 519-22.
30. Nicoll R, Kauer J, Malenka R The current excitement in long-term potentiation. Neuron 1988,1:97-103
31. Ascher P, Nowak S. Electrophysiological studies of NMDA receptors Trends Neurosci 1978;1:284-8.
32. Javitt D, Zukin S. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 1991;148:1301-8
33. Cotman C, Monaghan D, Ganong A. Excitatory amino acid neurotransmission. NMDA receptors and Hebb-type synaptic plasticity. Annu Rev Neurosci 1988;11:61-80
34. Deutsch S, Mastropaolo J, Schwartz B, Rosse R, Morihisa J. A "glutamatergic hypothesis" of schizophrenia: rationale for pharmacotherapy with glycine. Clin Neuropharmacol 1989,12:1-13.
35. Thomson A. Glycine modulation of the NMDA receptor/channel complex. Trends Neurosci 1989;12:349-52.
36. 3H]MK-801 binding to the N-methyl-D-aspartate receptor-ion channel complex by L-gtutamate, glycine, and polyamines J Neurochem 1988;51 830-6
37. 3H]MK-801 to the N-methyl-D-aspartate receptor: pharmacological evidence for the existence of a polyamine recognition site Mol Pharmacol 1989,36:575-81.
38. Nowak L, Bregestovski P, Ascher P, Herbet A, Prochiantz A. Magnesium gates glutamate-activated channels in mouse central neurones Nature 1984;307:462-5.
39. 2+ of NMDA responses in spinal cord neurones. Nature 1984;309:261-3
40. Collingridge G, Herron C, Lester R. Frequency-dependent N-methyl-D-aspartate receptor-mediated synaptic transmission in rat hippocampus J Physiol 1988;399:301-21
41. Nicoll R, Malenka R, Kauer J. Functional comparison of neurotransmitter receptor subtypes in mammalian central nervous system. Physiol Rev 1990;70:513-65.
42. MacDermott A, Dale N Receptors, ion channels and synaptic potentials underlying the integrative actions of excitatory amino acids Trends Neurosci 1987,10:280-4.
43. 3H]MK-801 binding to the NMDA receptor/ionophore complex is regulated by divalent cations: evidence for multiple regulatory sites Eur J Pharmacol 1988;151:103-12.
44. 3H) glutamate binding sites in rat brain. Neuroscience 1985,5.2909-19
45. Storm-Mathisen J, Ottersen OP. Anatomy of putative glutamatergic neurons. In: Avoli M, Reader TA, Dykes RW, Gloor P, eds Neurotransmitters and cortical function from molecules to mind. New York: Plenum Press, 1988:39-70
46. 3H]MK-801 binding sites in the human brain. Brain Res 1989;489.397-9.
47. Gruzelier A, Seymour K, Wilson L, Jolley A, Hirsch S. Impairments on neuropsychologic tests of temporohippocampal and frontohippocampal functions and word fluency in remitting schizophrenia and affective disorders. Arch Gen Psychiatry 1988,45:623-9.
48. Goldberg TE, Weinberger DR, Berman KF, Pliskin NH, Podd MH. Further evidence for dementia of the prefrontal type in schizophrenia? Arch Gen Psychiatry 1987;44: 1008-14.
49. Squires R, Saederup E. A review of evidence for GABAergic predominance/glutamatergic deficit as a common etiological factor in both schizophrenia and affective psychosis more support for a continuum hypothesis of "functional" psychosis Neurochem Res 1991;16 1099-1111
50. Grace A. Phasic versus tonic dopamine release and the modulation of dopamine system responsivity: a hypothesis for the etiology of schizophrenia. Neuroscience 1991;41:1-24.
51. Olney J. Glutamatergic mechanisms m neuropsychiatry. In: Meltzer HY, ed. Novel antipsychotic drugs. New York: Raven Press, 1992:37-49.
52. Pin J, Van-Vliet B, Bockaert J. NMDA and kainate-evoked GABA release from striatal neurons differentiated in primary culture: differential blocking by phencyclidine. Neurosci Lett 1988;87 87-92.
53. Stelzer A, Wong R. GABA responses in hippocampal neurons are potentiated by glutamate [letter]. Nature 1989;337:170-3.
54. Janaky R, Saransaari P, Oja SS. Release of GABA from rat hippocampal slices. involvement of quisqualate/N-methyl-D-aspartate-gated ionophores and extracellular magnesium. Neuroscience 1993;53 779-85
55. Scatton B, Worms P, Lloyd K, Bartholini G. Cortical modulation of striatal function. Brain Res 1982;232:331-43
56. Nicollon A, Krekerian L, Duticier N. Presynaptic controls in the neostriatum: reciprocal interactions between the nigrostriatal dopaminergic neurons and the cortico-striatal glutamatergic pathway. Exp Brain Res 1983;7 54-65.
57. Donzanti B, Uretsky N. Effects of excitatory amino acids on locomotor activity after bilateral microinjection into the rat nucleus accumbens. possible dependence on dopaminergic mechanisms. Neuropharmacology 1983;8:971-81
58. 3H]dopamine release from rat striatum: an in vitro model for glutamate actions. J Neurochem 1979;32 1539-45.
59. Collingridge G, Bliss T. NMDA receptors-their role in long-term potentiation. Trends Neurosci 1978,1:288-93.
60. Collingridge G. Long-term potentiation in the hippocampus: mechanisms of initiation and modulation by neurotransmitters. Trends Pharmacol Sci 1985;6:407-13.
61. Teyler T, Discenna P. Long-term potentiation Annu Rev Neurosci 1987;10:131-61.
62. Lovinger D, Colley P, Akers R, Nelson R, Routtenberg A. Direct relation of long-term synaptic potentiation to phosphorylation of membrane protein F1, a substrate for membrane protein kinase C. Brain Res 1986;399:205-11
63. Snipes G, Chan S, McGuire C, et al. Evidence for the coidentification of GAP-43, a growth-associated protein, and F1, a plasticity-associated protein. J Neurosci 1987,7: 4066-75
64. MacDonald J, Bartlett M, Mody I, Reynolds J, Salter M. The PCP site of the NMDA receptor complex Adv Exp Med Biol 1990,268.27-34.
65. Walberg C, McCarron M, Schuze B. Quantitation of phencyclidine in serum by enzyme immunoassay results m 405 patients. J Anal Toxicol 1983;7:106-10
66. Pearce D. Detection and quantitation of phencyclidine in blood by use of [(2)H(5)]phencyclidine and select ion monitoring applied to non-fatal cases of phencyclidine intoxication. Clin Chem 1976;22:1623-6.
67. Carlsson M, Carlson A. The NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted mice. J Neural Transm 1989;75:221-6.
68. Hitri A, O'Connor DA, Cohen JM, Keuler DJ, Deutsch SI. Differentiation between MK-801- and apomorphine-induced stereotyped behaviors in mice. Clin Neuropharmacol 1993;16:220-36.
69. Koek W, Colpaert F, Woods J, Kamenka J-M. The phencyclidine (PCP) analog N-[1(2-benzo(B)thiophenyl)cyclohexyl] piperidine shares cocaine-like but not other characteristic behavioral effects with PCP, ketamine and MK-801 J Pharmacol Exp Ther 1989,250.1019-27.
70. Schmidt W. Intrastriatal injection of DL-2-amino-5-phosphonovaleric acid (AP-5) induces sniffing stereotypy that is antagonized by haloperidol and clozapine. Psychopharmacology 1986,90:123-30
71. Jones S, Snell L, Johnson K. Inhibition by phencyclidine of excitatory amino acid-stimulated release of neurotransmitter in the nucleus accumbens. Neuropharmacology 1987;26 173-9
72. Tassin J, Thierry A, Blanc G, Glowinski J. Evidence for a specific uptake of dopamine by dopaminergic terminals of the rat cerebral cortex. Naunyn Schmiedebergs Arch Pharmacol 1974;282.239-44
73. Maura G, Barzizza A, Lottero P, Raiteri M. The excitatory ammo acid-releasing nerve terminals in rat striatum possess D-2 dopamine receptors mediating inhibition of release. Neurochem Int 1990;16:53.
74. Rowlands G, Roberts P. Activation of dopamine receptors inhibits calcium-dependent glutamate release from corticostriatal terminals in vitro Eur J Pharmacol 1980;62 241-7.
75. Stringer J, Greenfield L, Hackett J, Guyenet P. Blockade of long-term potentiation by phencyclidine and sigma opiates in the hippocampus in vivo and in vitro Brain Res 1983;280 127-38
76. Morris R, Anderson E, Lynch G, Baudry M. Selective impairment of learning and blockade of long-term potentiation by an N-methyl-D-aspartate receptor antagonist, AP5. Nature 1986,319:774-6
77. Somogyi P. Synaptic organization and transmitters of intracortical circuits. In: Goldman-Rakic P, ed. Cerebral cortex as a unified structure Washington, DC: Society for Neuroscience, 1987.143-55
78. Jones EG. GABA neurons and their cotransmitters in the primate cerebral cortex In Avoli M, Reader TA, Dykes RW, Gloor P, eds. Neurotransmitters and cortical function from molecules to mind. New York: Plenum Press, 1988:125-52.
79. Gattaz WF, Gattaz D, Beckmann H. Glutamate in schizophrenics and healthy controls. Arch Psychiatr Nervenkr 1982;231:221-5.
80. Perry T. Normal cerebrospinal fluid and brain glutamate levels in schizophrenia do not support the hypothesis of glutamatergic neuronal dysfunction Neurosci Lett 1982,28:81-5
81. Ferrarese C, Pecora N, Frigo M, Appollonio I, Frattola L. Assessment of reliability and biological significance of glutamate levels in cerebrospinal fluid. Ann Neurol 1993,33 316-19.
82. Baruah S, Waziri R, Hegwood T, Mallis L. Plasma serine in schizophrenics and controls measured by gas chromatography-mass spectrometry. Psychiatry Res 1991;37:261-70.
83. Korpi E, Kaufmann C, Marnela K, Weinberger D. Cerebrospinal fluid amino acid concentrations in chronic schizophrenia. Psychiatry Res 1987;20.337-45.
84. Perry T, Hansen S. Interconversion of serine and glycine is normal in psychotic patients. Psychiatry Res 1985:15:109-13
85. Waziri R. Glycine therapy of schizophrenia [letter]. Biol Psychiatry 1988,23 210
86. Waziri R, Baruah S, Hegwood T, Sherman A. Abnormal serine hydroxymethyl transferase activity in the temporal lobes of schizophrenics. Neurosci Lett 1990,120.237-40.
87. Waziri R, Baruah S, Sherman AD. Abnormal senne-glycine metabolism m the brains of schizophrenics. Schizophr Res 1993;8:233-43
88. Carl GF, Brogan MP, Young BK. Is plasma serine a marker for psychosis' Biol Psychiatry 1992;1:1130-5.
89. Devor EJ, Waziri R. A familial/genetic study of plasma senne and glycine concentrations. Biol Psychiatry 1993,34:221-5.
90. Costa J, Khaled E, Sramek J, Bunney W, Potkin S. An open trial of glycine as an adjunct to neuroleptics in chronic treatment-refractory schizophrenics [letter]. J Clin Psychopharmacol 1990;10:71-2.
91. Rosse R, Theut S, Banay-Schwartz M, et al. Glycine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: an open-label, pilot study. Clin Neuropharmacol 1989;12:416-24.
92. Javitt D, Zylberman I, Zukin S, Heresco-Levy R, Lindenmayer J. Amelioration of negative symptoms in schizophrenia by glycine. Am J Psychiatry 1994;151:1234-6.
93. Rosse R, Schwartz B, Leighton M, Davis R, Deutsch S. An open-label trial of milacemide in schizophrenia: an NMDA intervention strategy. Clin Neuropharmacol 1990;13: 348-54.
94. Rosse R, Schwartz B, Davis R, Deutsch S. An NMDA intervention strategy in schizophrenia with "low-dose" milacemide. Clin Neuropharmacol 1991;14:268-72.
95. Zukin S, Javitt D. The brain NMDA receptor, psychotomimetic drug effects, and schizophrenia. In: Tasman A, Goldfinger S, eds Review of psychiatry. Washington, DC: American Psychiatric Press, 1991 243-51
96. Hirsch S, Richardson-Andrews R, Costall B, Kelly M, de Belleroche J, Naylor R. The effects of some polyammes on putative behavioral indices of mesolimbic versus striatal dopaminergic function. Psychopharmacology 1987;93:101-4.
97. Zukin S, Zukin R, Vale W, et al. An endogenous ligand of the brain σ/PCP receptor antagonizes NMDA-induced neurotransmitter release. Brain Res 1987,416:84-9.
98. Su T, Weissman A, Yeh S. Endogenous ligands for sigma opioid receptors in the brain ("sigmaphin"): evidence from binding assays. Life Sci 1986;38:2199-2210
99. Quirion R, DiMaggio D, French E, et al. Evidence for an endogenous peptide ligand for the phencyclidine receptor. Peptides 1984;5:967-73.
100. Johnson KM Jr. Neurochemistry and neurophysiology of phencyclidine In: Meltzer HY, ed. Psychopharmacology the third generation of progress New York: Raven Press, 1987:1581-8
101. Contreras PC, Gray NM, DiMaggio DA, et al. Isolation and characterization of an endogenous ligand for the PCP receptors from porcine, rat, and human tissue Sigma, PCP, and NMDA receptors. National Institute on Drug Abuse Research monograph series 133. NIH publication no. 93-3587 Washington, DC: U S Government Printing Office, 1993:207-23.
102. Contreras P, DiMaggio D, O'Donohue T. An endogenous ligand for the sigma opioid binding site. Synapse 1987;1.57-61
103. Rao T, Mick S, Cler J, et al. Effects of sigma ligands on mouse cerebellar cyclic guanosine monophosphate (cGMP) levels in vivo: further evidence for a functional modulation of N-methyl-D-aspartate (NMDA) receptor complex-mediated events by sigma ligands Brain Res 1991,561:43-50.
104. Javitt D, Jotkowitz A, Sircar R, Zukin S. Non-competitive regulation of phencyclidine/σ-receptors by the N-methyl-D-aspartate receptor antagonist D-(-)-2-amino-5-phosphonovaleric acid. Neurosci Lett 1987,78 193-8.
105. Deutsch S, Weizman A, Goldman M, Morihisa J. The sigma receptor: a novel site implicated in psychosis and antipsychotic drug efficacy Clin Neuropharmacol 1988,11.105-19
106. Chouinard G, Annable L. An early phase II clinical trial of BW234U in the treatment of acute schizophrenia in newly admitted patients Psychopharmacology 1984,84:282-4
107. Davidson F, Miller R, Wingfield M, Zung W, Dren A. The first clinical study of BW-234U in schizophrenia. Psychopharmacol Bull 1982;18:173-6
108. Guy W, Manov G, Wilson W, et al. Psychotropic actions of BW234U in the treatment of inpatient schizophrenics, a dose-range study. Drug Dev Res 1983;3:245-52.
109. Schwarcz G, Halaris A, Dren A, Manberg P. Open label evaluation of the novel antipsychotic compound BW234U in chrome schizophrenics. Drug Dev Res 1985;5:387-93.
110. Gewirtz GR, Gorman JM, Volavka J, et al. BMY 14802, a sigma receptor ligand for the treatment of schizophrenia. Neuropsychopharmacology 1994;10:37-40.
111. Junien J, Leonard B. Drugs acting on σ and phencyclidine receptors: a review of their nature, function, and possible therapeutic importance. Clin Neuropharmacol 1989;12. 353-74.
112. Olney J. Glutamate-induced neuronal necrosis in the infant mouse hypothalamus: an electron microscopic study. J Neurophathol Exp Neurol 1971;30.75-90.
113. Rothman S, Olney J. Excitotoxicity and the NMDA receptor. Trends Neurosci 1978,1:299-302
114. Coyle JT. Excitotoxins. In: Meltzer HY, ed Psychopharmacology. the third generation of progress. New York: Raven Press, 1987:333-40.
115. Choi D. Glutamate neurotoxicity and diseases of the nervous system. Neuron 1988,1 623-34.
116. Bondy SC, LeBel CP. The relationship between excitotoxicity and oxidative stress in the central nervous system. Free Radic Biol Med 1993;14.633-42.
117. Choi DW. Excitotoxic cell death. J Neurobiol 1992,23:1261-76
118. Dubinsky JM. Intracellular calcium levels during the period of delayed excitotoxicity J Neurosci 1993,13:623-31.
119. Hirose K, Chan PH. Blockade of glutamate excitotoxicity and its clinical applications. Neurochem Res 1993;18:479-63.
120. Sun AY, Cheng Y, Bu Q, Oldfield F. The biochemical mechanisms of the excitotoxicity of kainic acid. Mol Chem Neuropathol 1992,17.51-63
121. Meldrum B, Garthwaite J. Excitatory amino acid neurotoxicity and neurodegenerative disease. Trends Pharmacol Sci 1990,11:379-87.
122. Mattson M, Rychlik B, You J, Sisken J. Sensitivity of cultured human embryonic cerebral cortical neurons to excitatory amino acid-induced calcium influx and neurotoxicity Brain Res 1991;542:97-106